New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 7, 2013
07:11 EDTMACKMerrimack pushes back top line data for NAPOLI-1 to Q2 of 2014
Merrimack now expects to report top line data for NAPOLI-1, its Phase 3 clinical trial of MM-398 in advanced pancreatic cancer, in Q2 of 2014. Merrimack previously disclosed that top line data was expected in Q4 of 2013 or Q1 of 2014. This change is based on a blinded assessment of overall survival events across the entire trial, which are occurring later than forecasted. As previously disclosed, Merrimack met its enrollment target for the trial in August 2013.
News For MACK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
11:55 EDTMACKMerrimack pipeline progressing despite MM-111 discontinuation, says Cantor
Subscribe for More Information
11:49 EDTMACKMerrimack stops MM-111 development after DSMB recommendation
Subscribe for More Information
07:29 EDTMACKMerrimack reports Q4 EPS (9c), consensus (19c)
Reports Q4 revenue $33.91M, consensus $28.78M.
February 19, 2015
08:17 EDTMACKMerrimack initiates Phase 2 biomarker-selected clinical trial of MM-121
Merrimack Pharmaceuticals announced the initiation of a global, open-label, biomarker-selected, randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive, locally advanced or metastatic non-small cell lung cancer. As part of this trial, Merrimack expects to enroll approximately 120 heregulin positive patients that will be randomized to receive either MM-121 plus the investigator's choice of docetaxel or pemetrexed, or the investigator's choice of docetaxel or pemetrexed alone.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use